Cagrilintide + Semaglutide (10 mg Blend) Dosage Protocol
Quickstart Highlights
Cagrilintide + Semaglutide is a dual‑agonist combination blending an amylin analog (cagrilintide) with a GLP‑1 receptor agonist (semaglutide). Clinical trials demonstrate superior weight reduction versus either agent alone, with the combination targeting complementary satiety pathways[1][2]. This educational protocol presents a once‑weekly subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.
- Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL total (1.67 mg/mL each peptide).
- Typical weekly range: 0.25–2.4 mg of each peptide once weekly (gradual titration over 16+ weeks).
- Easy measuring: At 3.33 mg/mL total, 1 unit = 0.01 mL ≈ 16.7 mcg each peptide on a U‑100 insulin syringe.
- Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days; avoid freeze–thaw cycles.
Dosing & Reconstitution Guide
Educational guide for reconstitution and weekly dosing
Standard / Gradual Titration (3 mL = ~3.33 mg/mL total)
Route: Subcutaneous injection. Frequency: Once weekly[1][3].
| Week/Phase | Dose per Peptide (mcg / mg) | Units (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg (0.25 mg) each | 15 units (0.15 mL) |
| Weeks 5–8 | 500 mcg (0.50 mg) each | 30 units (0.30 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) each | 60 units (0.60 mL) |
| Weeks 13–16 | 1700 mcg (1.7 mg) each | 102 units (1.02 mL) |
| Week 17+ | 2400 mcg (2.4 mg) each | 144 units (1.44 mL) |
Note: Each dose delivers equivalent amounts of both cagrilintide and semaglutide (e.g., 0.25 mg cagrilintide + 0.25 mg semaglutide at Week 1). The 2.4 mg target mirrors clinical trial protocols[1][2].
Reconstitution Math
- Vial contents: 5 mg cagrilintide + 5 mg semaglutide = 10 mg total blend
- Add: 3.0 mL bacteriostatic water
- Concentration: 10 mg ÷ 3.0 mL = 3.33 mg/mL total (1.67 mg/mL each peptide)
- Per unit (U‑100 syringe): 3333 mcg/mL × 0.01 mL = 33.3 mcg total per unit (16.7 mcg each peptide)
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until fully dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 30 days[7].
Supplies Needed
Plan based on an 8–16 week weekly protocol with gradual titration.
-
Peptide Vials (Cagrilintide + Semaglutide, 10 mg blend each):
- 8 weeks ≈ 1 vial (~6 mg total used)
- 12 weeks ≈ 2 vials (~14 mg total used)
- 16 weeks ≈ 3 vials (~27.6 mg total used)
-
Insulin Syringes (U‑100):
- Per week: 1 syringe (once weekly)
- 8 weeks: 8 syringes
- 12 weeks: 12 syringes
- 16 weeks: 16 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 16 weeks (3 vials): 9 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each week.
- Per week: 2 swabs
- 8 weeks: 16 swabs
- 12 weeks: 24 swabs
- 16 weeks: 32 swabs → recommend 1 × 100‑count box
Protocol Overview
Concise summary of the once‑weekly regimen.
- Goal: Support significant weight reduction through dual amylin + GLP‑1 receptor agonism[1][2].
- Schedule: Weekly subcutaneous injections for 16+ weeks (maintenance thereafter).
- Dose Range: 0.25–2.4 mg each peptide weekly with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL total) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; use within 30 days.
Dosing Protocol
Suggested weekly titration approach.
Storage Instructions
Proper storage preserves peptide quality[7].
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Important Notes
Practical considerations for consistency and safety.
- Use new sterile insulin syringes; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) weekly to reduce local irritation[6].
- Inject slowly; wait a few seconds before withdrawing the needle.
- Document weekly dose and site rotation to maintain consistency.
- Higher doses may increase GI side effects (nausea, reduced appetite); titrate gradually[3].
How This Works
Cagrilintide is a long‑acting amylin analog that reduces appetite via central satiety pathways, while semaglutide activates GLP‑1 receptors to enhance glucose‑dependent insulin secretion and suppress glucagon[4][5]. The combination leverages complementary mechanisms: amylin primarily delays gastric emptying and signals satiety through the area postrema, while GLP‑1 enhances pancreatic β‑cell function and central appetite suppression[1]. Clinical trials of the co‑administered regimen (CagriSema) show greater body‑weight reduction than either agent alone[2].
Potential Benefits & Side Effects
Observations from clinical literature.
- Weight reduction: Phase 2 trials report mean body‑weight loss of ~15–17% at 32 weeks with the combination, exceeding semaglutide monotherapy[2].
- Glycemic control: In type 2 diabetes, HbA1c reductions were observed alongside weight loss[1].
- GI tolerability: Nausea, vomiting, and diarrhea are the most common adverse events; gradual titration minimizes severity[3].
- Injection‑site reactions: Mild and transient in clinical reports.
Lifestyle Factors
Complementary strategies for best outcomes.
- Pair with a balanced, protein‑forward diet tailored to energy needs.
- Combine resistance training and aerobic activity to reinforce metabolic adaptations.
- Prioritize sleep and stress management to support adherence and recovery.
- Stay hydrated and eat slowly to reduce GI discomfort.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[8][9].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[8].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[9].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[6].
- For volumes exceeding 1 mL (e.g., 1.44 mL at maintenance dose), inject slowly over several seconds.
Recommended Source
We recommend Pure Lab Peptides for high‑purity Cagrilintide + Semaglutide (10 mg Blend).
Why Pure Lab Peptides?
- High‑purity, third‑party‑tested lots with batch COAs.
- Consistent, ISO‑aligned handling and documentation.
- Reliable fulfillment to maintain cold‑chain integrity.
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.
References
-
Lancet Diabetes Endocrinology (2024)
— Efficacy and safety of co‑administered once‑weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes: phase 2 trial -
Lancet (2021)
— Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with semaglutide 2.4 mg: phase 1b trial -
Lancet (2021)
— Once‑weekly cagrilintide for weight management: dose‑finding phase 2 trial in overweight/obesity -
StatPearls (2025)
— Semaglutide: pharmacology, indications, and clinical use overview -
Cureus (2024)
— Semaglutide: risks and benefits review (PMC) -
WHO (2010)
— Best practices for injection and related procedures (WHO toolkit) -
Sigma‑Aldrich (2016)
— Peptide Handling Guide: storage, reconstitution, and stability -
LibreTexts (2020)
— Intradermal and subcutaneous injections: clinical procedures -
CDC (2024)
— Vaccine administration: subcutaneous injection technique -
PubMed (2024)
— Cagrilintide‑semaglutide in adults with overweight/obesity and type 2 diabetes -
ScienceDirect (2024)
— Efficacy and safety of CagriSema 2.4 mg + 2.4 mg in type 2 diabetes -
PMC (2019)
— Subcutaneous drug injection: pharmacologic review -
Pure Lab Peptides
— Cagrilintide + Semaglutide (10 mg Blend) product page